Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imetelstat in Myelofibrosis and Other Myeloid Malignancies
NCT01731951Phase 2Completed
- Sponsor
- Geron Corporation
- Start
- Oct 2012
- Primary completion
- May 2018
- Modality
- Antisense DNA, Small Interfering RNA (siRNA), MicroRNA (miRNA)
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of imetelstat in myelofibrosis (MF), acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and 1 more (6 arms), sponsored by Geron Corporation. Primary endpoint: Overall Response Rate. Started Oct 2012; status: completed.
02
Drugs
imetelstat
03
Conditions
myelofibrosis (MF)acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)myelodysplastic/myeloproliferative neoplasm (MDS/MPN)
Beyond the preview
Go deeper on NCT01731951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01731951.